• Consensus Rating: Buy
  • Consensus Price Target: $9.80
  • Forecasted Upside: 118.75 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.48
▼ -0.1 (-2.18%)

This chart shows the closing price for IMGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunoGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMGN

Analyst Price Target is $9.80
▲ +118.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ImmunoGen in the last 3 months. The average price target is $9.80, with a high forecast of $18.00 and a low forecast of $5.00. The average price target represents a 118.75% upside from the last price of $4.48.

This chart shows the closing price for IMGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in ImmunoGen. This rating has held steady since November 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022BarclaysInitiated CoverageOverweight$8.00Low
3/21/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$9.00 ➝ $6.00High
2/22/2022SVB LeerinkLower TargetMarket Perform$7.00 ➝ $5.00Low
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$18.00Medium
12/1/2021Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $12.00High
11/30/2021Royal Bank of CanadaBoost TargetPositive ➝ Outperform$8.00 ➝ $9.00High
10/29/2021SVB LeerinkLower TargetMarket Perform$6.00 ➝ $5.00High
5/10/2021William BlairReiterated RatingOutperformHigh
2/16/2021HC WainwrightBoost TargetBuy$11.00 ➝ $12.00Low
12/7/2020Piper SandlerBoost TargetNeutral$5.50 ➝ $6.50Medium
11/9/2020HC WainwrightReiterated RatingBuyMedium
11/6/2020SVB LeerinkBoost TargetMarket Perform$5.00 ➝ $6.00Low
10/26/2020HC WainwrightReiterated RatingBuy$11.00Low
10/6/2020SVB LeerinkBoost TargetMarket Perform$4.00 ➝ $5.00Medium
10/2/2020GuggenheimUpgradeNeutral ➝ Buy$14.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
9/18/2020William BlairReiterated RatingBuyHigh
6/1/2020HC WainwrightReiterated RatingBuy$9.00Low
12/17/2019HC WainwrightReiterated RatingBuy$5.00 ➝ $9.00High
12/10/2019HC WainwrightReiterated RatingBuy$5.00Low
12/10/2019CowenReiterated RatingBuyLow
9/30/2019CowenReiterated RatingBuyHigh
9/24/2019SVB LeerinkReiterated RatingHoldMedium
8/13/2019HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $5.00Low
6/28/2019HC WainwrightSet TargetBuy$4.00High
6/27/2019CowenReiterated RatingBuyHigh
6/2/2019CowenReiterated RatingBuyMedium
5/16/2019HC WainwrightLower TargetBuy$7.00 ➝ $4.00High
5/15/2019GuggenheimDowngradeBuy ➝ NeutralHigh
5/6/2019HC WainwrightUpgradeNeutral ➝ Buy$7.00High
5/6/2019CowenUpgradeMarket Perform ➝ Outperform$2.94High
3/19/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
3/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$2.68Low
3/4/2019SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
3/4/2019HC WainwrightDowngradeBuy ➝ Neutral$18.00 ➝ $3.50Medium
3/1/2019SVB LeerinkDowngradeOutperform ➝ Market PerformMedium
3/1/2019CowenReiterated RatingHoldHigh
3/1/2019Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
3/1/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$13.00 ➝ $2.50High
1/3/2019HC WainwrightReiterated RatingBuyMedium
12/3/2018HC WainwrightSet TargetBuy$18.00Low
12/2/2018Piper Jaffray CompaniesSet TargetBuy$14.00Medium
11/6/2018HC WainwrightSet TargetBuy$18.00High
10/31/2018HC WainwrightSet TargetBuy$18.00Medium
10/22/2018William BlairReiterated RatingOutperformHigh
10/22/2018HC WainwrightSet TargetBuy$18.00High
10/8/2018HC WainwrightSet TargetBuy$18.00High
9/17/2018GuggenheimInitiated CoverageBuyLow
9/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightLow
7/30/2018HC WainwrightReiterated RatingBuy$18.00Medium
7/27/2018CowenReiterated RatingHoldHigh
6/13/2018HC WainwrightSet TargetBuy$18.00High
6/5/2018HC WainwrightSet TargetBuy$18.00High
5/17/2018CowenReiterated RatingHoldMedium
5/17/2018HC WainwrightSet TargetBuy$18.00Medium
5/7/2018HC WainwrightSet TargetBuy$18.00High
4/25/2018HC WainwrightSet TargetBuy$18.00Low
4/10/2018HC WainwrightSet TargetBuy$18.00High
4/8/2018Cantor FitzgeraldSet TargetHold$5.00Low
3/26/2018SVB LeerinkReiterated RatingOutperformMedium
3/26/2018HC WainwrightSet TargetBuy$18.00High
3/25/2018Cantor FitzgeraldSet TargetHold$5.00High
3/21/2018Royal Bank of CanadaBoost TargetOutperform$16.00Low
3/12/2018HC WainwrightSet TargetBuy$18.00Medium
2/12/2018HC WainwrightSet TargetBuy$18.00High
2/8/2018Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$12.00Medium
1/31/2018HC WainwrightInitiated CoverageBuy ➝ BuyHigh
11/3/2017Cantor FitzgeraldReiterated RatingHold$5.00N/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$9.00N/A
(Data available from 9/26/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
2/28/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
3/30/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/29/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
5/29/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/28/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/28/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
8/27/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
9/26/2022

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
ImmunoGen logo
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $4.48
Low: $4.46
High: $4.74

50 Day Range

MA: $5.35
Low: $4.48
High: $6.47

52 Week Range

Now: $4.48
Low: $3.10
High: $7.77

Volume

1,696,370 shs

Average Volume

3,394,545 shs

Market Capitalization

$988.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoGen?

The following sell-side analysts have issued research reports on ImmunoGen in the last twelve months: Barclays PLC, BMO Capital Markets, Jefferies Financial Group Inc., Royal Bank of Canada, StockNews.com, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for IMGN.

What is the current price target for ImmunoGen?

5 Wall Street analysts have set twelve-month price targets for ImmunoGen in the last year. Their average twelve-month price target is $9.80, suggesting a possible upside of 118.8%. BMO Capital Markets has the highest price target set, predicting IMGN will reach $18.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $5.00 for ImmunoGen in the next year.
View the latest price targets for IMGN.

What is the current consensus analyst rating for ImmunoGen?

ImmunoGen currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMGN will outperform the market and that investors should add to their positions of ImmunoGen.
View the latest ratings for IMGN.

What other companies compete with ImmunoGen?

How do I contact ImmunoGen's investor relations team?

ImmunoGen's physical mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company's listed phone number is (781) 895-0600 and its investor relations email address is [email protected] The official website for ImmunoGen is www.immunogen.com. Learn More about contacing ImmunoGen investor relations.